Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)

Wiley - Tập 76 Số 3 - Trang 325-336 - 1995
Paul Abrams1,2, Claude Schulman3,4, Sigmund Vaage5,6
1MD, FRCS, Consultant Urological Surgeon.
2Southmead Hospital, Bristol, UK
3MD, PhD, Professor of Urology.
4†Hôpital Universitaire Erasme, Brussels, Belgium and Stavanger, Norway
5MD, Chief Urological Surgeon.
6‡Rogaland Sentralsykehus, Stavanger, Norway

Tóm tắt

Objective To evaluate the efficacy and safety of tamsulosin 0.4 mg once daily (as a modified‐release formulation) compared with placebo in patients with benign prostatic enlargement, lower urinary tract symptoms and prostatic ‘obstruction’ (symptomatic benign prostatic hyperplasia [BPH]).Patients and methods Of 313 patients with symptomatic BPH enrolled in a 2‐week placebo run‐in period, 296 were subsequently randomized to receive either placebo (98 patients) or tamsulosin 0.4 mg once daily (198 patients) for 12 weeks. The primary variables assessed to determine efficacy were maximum urinary flow rate (Qmax) from free‐flow measurements and the total Boyarsky symptom score.Results Tamsulosin produced greater improvements in Qmax (1.4 mL/s, 13.1%) than did placebo (0.4 mL/s, 3.8%) (P= 0.028) and a greater decrease in total symptom score (3.4 points, 35.8% reduction) than did placebo (2.2 points, 23.7% reduction) (P= 0.002). Significantly more tamsulosin‐treated patients (67%) than placebo‐treated patients (44%) had a ≥ 25% decrease in total symptom score after 12 weeks (P < 0.001). Treatment with tamsulosin for 12 weeks also produced significant improvements in average urinary flow rate (P= 0.040), irritative (P= 0.013) and obstructive (P= 0.014) symptom scores and symptoms of nocturia (P= 0.022) and hesitancy (P= 0.004). Tamsulosin was tolerated well by the patients. The incidence of adverse events emerging during treatment was comparable in the tamsulosin‐and placebo‐treated groups (34% and 24% respectively, P= 0.109), as was the incidence of cardiovascular‐related adverse events (5% and 7% respectively; P= 0.596). There were no significant differences in changes in blood pressure or pulse rates between the tamsulosin‐and placebo‐treated groups.Conclusion Tamsulosin 0.4 mg once daily is safe, well tolerated and clinically effective in improving symptoms and urinary flow rate in patients with symptomatic BPH.

Từ khóa


Tài liệu tham khảo

10.1016/S0022-5347(17)49698-4

10.1016/0140-6736(91)90543-X

Caine M., 1990, Alpha‐adrenergic blockers for the treatment of benign prostatic hyperplasia, Urol Clin North Am, 17, 641, 10.1016/S0094-0143(21)00977-0

10.1136/bmj.308.6934.929

10.1002/pros.2990170508

10.2165/00003495-199447010-00005

10.1002/pros.2990170506

10.1056/NEJM199210223271701

10.1007/BF00184712

10.1016/S0022-5347(17)53216-4

10.1016/S0022-5347(17)47185-0

10.1016/0024-3205(94)90141-4

10.1016/S0022-5347(17)36941-0

10.1001/archfami.2.9.929

10.2165/00003495-199345030-00008

10.1016/0140-6736(91)93140-5

10.1111/j.1464-410X.1994.tb16546.x

10.1016/0165-6147(94)90136-8

Lepor H., 1993, Alpha1 adrenoceptor subtypes in the human prostate, J Urol, 149, 640, 10.1016/S0022-5347(17)36170-0

10.1002/pros.2990220404

10.1111/j.1464-410X.1994.tb09188.x

Miranda HF, 1994, α1A‐Adrenergic receptors in the isolated human prostate, Pharmacol Commun, 4, 181

10.1007/BF00171338

MichelMC GrübbelB. MöllhoffS.et al.1‐Adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate rat tissues and at cloned subtypes.Proc 23rd Congress Societé Internationale d'Urologie Sydney 18–22 September 1994:254(Abstract 649).

Forray C., 1994, The α1‐adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1c subtype, Mol Pharmacol, 45, 703

10.1111/j.1476-5381.1994.tb17053.x

10.1254/jjp.62.297

ChappieCR CouldwellCJ NobleAJ Chess‐WilliamsR.The in vitro α1‐adrenoceptor mediated effects of tamsulosin on the human prostate.Proc 23rd Congress Societé Internationale d'Urologie Sydney 18–22 September 1994:210(Abstract 487).

MinnemanKP HanC. HollingerS.Binding of3H‐tamsulosin to α1‐adrenergic receptor (AR) subtypes.Proc 23rd Congress Societé Internationale d'Urologie Sydney 18–22 September 1994262 (Abstract 680).

SchwinnD. WilsonK. PageS. CampbellS. KwatraM.Tamsulosin is selective for cloned α1c‐AR and α1A/Dsubtypes.Proc 23rd Congress Societé Internationale d'Urologie Sydney 18–22 September 1994: 261 (Abstract 678).

10.1016/0922-4106(95)90195-7

10.1016/S0022-5347(17)39620-9

Boyarsky S., 1977, A new look at bladder neck obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy, Trans Am Assoc Genitourinary Surg, 68, 29

AsoY. Boccon‐GibodL. DaSilvaFCet al.Subjective response objective response impact on quality of life. InCockettATK AsoY. DenisL. KhouryS. (eds.).Proceedings of the International Consultation on Benign Prostatic Hyperplasia (BPH). Paris June 2627 1991:85–90.

10.1111/j.1464-410X.1992.tb15665.x

10.1016/S0022-5347(17)40012-7

10.1111/j.1464-410X.1981.tb03273.x

10.1001/jama.1988.03720200040030

10.1016/S0022-5347(17)35640-9

10.1016/S0022-5347(17)35482-4

10.1016/S0022-5347(17)35544-1

SchalkenJA VanStratumP. SmitF.et al.Differential expression of alphal‐adrenergic receptor subtypes in BPH determined by reverse transcriptase PCR (Polymerase Chain Reaction).Proceedings of the 23rd Congress of the Societé Internationale d'Urologie Sydney 18–22 September 1994:253(Abstract 648).

10.1111/j.1440-1681.1994.tb02534.x

Thông tin
Thông tin xuất bản

Wiley

Tập 76 Số 3

325-336

Thông tin tác giả